


IFW



**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

INFORMATION DISCLOSURE STATEMENT		Docket Number: 1662/63402	
Application Number 10/825,386	Filing Date April 14, 2004	Examiner Unassigned	Art Unit 1621
Invention Title Hydrogenation of Imine of Sertraline with Catalysts		Inventors Mordechay HERSKOWITZ, et al.	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandra, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Mail Stop: Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date: 4/11/05

Signature: Julie Innes.

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.

4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due the Commissioner is authorized to charge deposit account number **11-0600** for such fees.

Respectfully submitted,

Date: April 11, 05

By Payam Moradian
Payam Moradian
Reg. No. 52,048

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO-1449**

ATTY. DOCKET NO.
1662/63402

SERIAL NO.
10/825,386

APPLICANT
Mordechay HERSKOWITZ et al.

FILING DATE
April 14, 2004

GROUP
1621

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	4,536,518*	August 20, 1985	Willard M. Welch, Jr., et al.			
	6,593,496*	July 15, 2003	George H. Quallich, et al.			
	US 2003/0105364*	June 5, 2003	Laurent Berger, et al.			
	US 2003/0166970*	September 4, 2003	Marioara Mendelovici, et al.			

* A copy is not enclosed since the present application was filed after June 30, 2003. (See OG Dated: August 5, 2003)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/30742	May 3, 2001	PCT				
	WO 98/27050	June 25, 1998	PCT				
	WO 01/16089	March 8, 2001	PCT				
	WO 99/57093	November 11, 1999	PCT				
	EP 1,059,287	December 13, 2000	EP				
	WO 01/49638	July 12, 2001	PCT				
	WO 99/47486	September 23, 1999	PCT				
	WO 01/09080	February 8, 2001	PCT				
	WO 02/102761	December 27, 2002	PCT				
	WO 01/68566	September 20, 2001	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	